Cancer, MetastaticNCT03452774
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
An observational study of Cancer, Metastatic and Cancer, run by Massive Bio, Inc. at 68 sites in 2 countries.
Trial summary
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment… Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Cancer, Metastatic, Cancer, Cancer of Pancreas
- What is being tested?
- Clinical Trial Matching
- How many people
- 50,000 participants
- Where
- 68 sitesin 2 countries
- Study dates
- 1 Jan 2018to Jun 2040
- How long will I take part?
- 36 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: Observational cohort study of eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider clinical trial enrollment (CTE) has already been made by their primary providers (PP).
Who may be able to join
- Pts with solid and hematological malignancies;
- Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2/Neu, Tumor mutational burden/load (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A/B, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1/2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA/B/C, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.
- These biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform
- Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and/or patient
Who cannot join
- ECOG PS > 2;
- Abnormal organ function;
- Hospice enrollment
Trial locations and contacts
68 sites in 2 countries. Contact the study team or a site near you to ask about taking part.
68 sites in 2 countries
United States67 sites, 67 recruiting
- Recruiting
Massive Bio SYNERGY-AI site
Albuquerque, New Mexico, 87131
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Ann Arbor, Michigan, 48109
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Atlanta, Georgia, 30322
Fiona Evans, + 1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Aurora, Colorado, 80045
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Baltimore, Maryland, 21218
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Bethesda, Maryland, 20892
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Billings, Montana, 59102
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Birmingham, Alabama, 35294
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Boise, Idaho, 83706
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Buffalo, New York, 14263
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Chapel Hill, North Carolina, 27514
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Charlottesville, Virginia, 22908
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Chicago, Illinois, 60611
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Cincinnati, Ohio, 45219
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Columbus, Ohio, 43210
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Dallas, Texas, 75246
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Denver, Colorado, 80218
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Duarte, California, 91010
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Duluth, Minnesota, 55805
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Fargo, North Dakota, 58102
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Greenville, South Carolina, 29605
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Hartford, Connecticut, 06102
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Hattiesburg, Mississippi, 39401
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Hempstead, New York, 11042
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Houston, Texas, 77030
Fiona Evans, + 1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Iowa City, Iowa, 52242
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Irvine, California, 92618
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Jacksonville, Florida, 32224
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Kansas City, Missouri, 64111
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
La Jolla, California, 92093
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Lansing, Michigan, 48912
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Little Rock, Arkansas, 72205
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Littleton, Colorado, 80129
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Manhasset, New York, 11030
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Mayfield Heights, Ohio, 44124
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Memphis, Tennessee, 38105
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Miami, Florida, 33136
Fiona Evans, + 1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Milwaukee, Wisconsin, 53226
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Mobile, Alabama, 36604
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Morgantown, West Virginia, 26506
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Nashville, Tennessee, 37203
Fiona Evans, + 1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
New Brunswick, New Jersey, 08901
Fiona Evans, + 1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
New Orleans, Louisiana, 70112
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
New York, New York, 10006
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Newark, Delaware, 19713
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Norwalk, Connecticut, 06856
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Omaha, Nebraska, 68124
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Orange, California, 92868
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Philadelphia, Pennsylvania, 19044
Fiona Evans, + 1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Portland, Oregon, 97239
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Providence, Rhode Island, 02903
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Salt Lake City, Utah, 84112
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
San Francisco, California, 94143
Fiona Evans, + 1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Savannah, Georgia, 31405
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Scarborough, Maine, 04074
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Scottsdale, Arizona, 85260
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Seattle, Washington, 98109
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Silver Spring, Maryland, 20904
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
St Louis, Missouri, 63110
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Stanford, California, 94305
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Staten Island, New York, 10314
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Tampa, Florida, 33612
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Temple, Texas, 76508
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Towson, Maryland, 21204
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Tulsa, Oklahoma, 74146
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Winston-Salem, North Carolina, 27157
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
- Recruiting
Massive Bio SYNERGY-AI site
Worcester, Massachusetts, 01655
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
Puerto Rico1 site, 1 recruiting
- Recruiting
Massive Bio SYNERGY-AI site
San Juan, 00917
Fiona Evans, +1 (844) 627-7246, fevans@massivebio.com
About this study
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
Read the detailed description
The SYNERGY Registry is an international prospective, observational cohort study of eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP). Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT. Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching. Patients voluntarily enroll into the registry, which is non-interventional with no protocol-mandated tests/procedures - all treatment decisions are made at the discretion of PP in consultation with their pts, based on the AI CT matching report, and VTB support. CTE will be assessed on variables including biomarkers, barriers to enrollment. Study duration anticipated as ~36 mo (~24-mo enrollment followed by 12 mo of data collection, to occur every 3 mo). The primary analysis will be performed 12 mo after last pt enrolled. The impact time to initiation of CTE on PFS and OS will be estimated by Kaplan-Meier and Cox multivariable survival analysis. Enrollment is ongoing, with a target of ≥50,000 patients.
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Stomach, Cancer Liver
- Being tested
- Clinical Trial Matching
- Keywords
- artificial intelligence, virtual tumor board, clinical trial, clinical trial matching, electronic medical record, machine learning, cost of care, targeted therapy, immunotherapy, precision medicine, precision oncology, cancer, value based care, real world data, data analytics
- Medical subject headings
- Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Liver Neoplasms, Stomach Neoplasms, Carcinoma, Hepatocellular, Rectal Neoplasms, Kidney Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Clinical Trial MatchingOther
Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT. Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching.
| Study group | Role | What they receive |
|---|---|---|
| Study Group | Eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP). Receives: Other: Clinical Trial Matching |
What is being measured
The primary outcome is the main question the study is designed to answer.
Proportion of patients Eligible for CTE versus Actual CTE
CTE Accrual
Measured: Through study completion, an average of 1 year
Secondary outcomes (6)
Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis
OS
Measured: 4 years
Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis
PFS
Measured: 4 years
Identification of Barriers to CTE
To identify barriers to accruals to clinical trials, as measured and reported by a questionnaire
Measured: Through study completion, an average of 1 year
Real World Data Analytics
To Analyze Individual Standard of Care Chemotherapy Utilization (nominal), across treatment lines (numeric); data will be combined and aggregated to report chemotherapy utilization rate (%).
Measured: Through study completion, an average of 1 year
Virtual Tumor Board Utilization
VTB Use Rate
Measured: Through study completion, an average of 1 year
Time from Intervention to Actual CTE (months)
Time to CTE
Measured: Through study completion, an average of 1 year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted2 Mar 2018
- Study start1 Jan 2018
- Primary completionDec 2038 (estimated)
- Study completionJun 2040 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Cancer, MetastaticStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 50,000 participants (estimated)
- Target duration
- 36 Months
Sponsor and investigators
- Lead sponsor
- Massive Bio, Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Selin Kurnaz, PhD, Principal investigator, Massive Bio, Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03452774
- Sponsor's protocol ID
- SYNERGY-AI
- Status last verified
- Oct 2025
- First submitted
- 13 Feb 2018
- Last updated
- 28 Oct 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- ClinicalTrials.gov ID
- NCT03452774
- Acronym / sponsor ID
- SYNERGY-AI
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Stomach, Cancer Liver
- Keywords
- artificial intelligence, virtual tumor board, clinical trial, clinical trial matching, electronic medical record, machine learning, cost of care, targeted therapy
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50,000 participants (estimated)
- Lead sponsor
- Massive Bio, Inc.Industry (pharma, biotech, devices)
- Study start
- 1 Jan 2018 (actual)
- Primary completion
- Dec 2038 (estimated)
- Study completion
- Jun 2040 (estimated)
- First posted
- 2 Mar 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.
Detailed description
The SYNERGY Registry is an international prospective, observational cohort study of eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP). Using a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT. Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching. Patients voluntarily enroll into the registry, which is non-interventional with no protocol-mandated tests/procedures - all treatment decisions are made at the discretion of PP in consultation with their pts, based on the AI CT matching report, and VTB support. CTE will be assessed on variables including biomarkers, barriers to enrollment. Study duration anticipated as ~36 mo (~24-mo enrollment followed by 12 mo of data collection, to occur every 3 mo). The primary analysis will be performed 12 mo after last pt enrolled. The impact time to initiation of CTE on PFS and OS will be estimated by Kaplan-Meier and Cox multivariable survival analysis. Enrollment is ongoing, with a target of ≥50,000 patients.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Target follow-up
- 36 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Study Group | – | Other: Clinical Trial MatchingEligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider CTE has already been made by their primary providers (PP). |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- Observational cohort study of eligible adult and pediatric pts with advanced solid and hematological malignancies, for whom the decision to consider clinical trial enrollment (CTE) has already been made by their primary providers (PP).
Key inclusion criteria (4 listed)
- Pts with solid and hematological malignancies;
- Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2, HER2/Neu, Tumor mutational burden/load (TMB), ABL1, ACVR1B, AKT1, AKT2, AKT3, ALK, APC, AR, ATM, ATRX, AURKA, AURKB, BAP1, BCL2, BCL6, BRAF, BRCA1, BRCA2, BTK, CCND1, CCND2, CCND3, CDK4, CDK6, CDKN1A/B, CEBPA, CHEK1, CHEK2, CSF1R, CTNNB1, DAXX, DDR1/2, DNMT3A, EGFR, ERBB2, ERBB3, ERBB4, ERCC4, ER, ESR1, FANCA, FAS, FBXW7, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, GATA3, GATA6, GNAS, HDAC1, HGF, HRAS, IDH1, IDH2, IGF1R, JAK1, JAK2, JAK3, KDR (VEGFR2), KIT, KRAS, MAP2K2 (MEK2), MAP3K1, MCL1, MDM2, MDM4, MEN1, MET, MSH2, MSH3, MSH6, MTOR, MUTYH, MYC, MYCL (MYCL1), NF1, NF2, NOTCH1, NPM1, NRAS, NTRK1, NTRK2, NTRK3, PALB2, PARP1, PARP2, PARP3, PBRM1, PDCD1 (PD1), PDCD1LG2 (PD-L2), PDGFRA, PDGFRB, PIK3C, PMS2, POLD1, POLE, PRDM1, PTCH1, PTEN, RAF1, RB1, RET, RICTOR, ROS1, RPTOR, SDHA/B/C, SMAD, SMARC, SMO, STK11, TGFBR2, TP53, TSC1, TSC2, VEGFA, VHL, WT1, ZNF217, ZNF703, CEACAM, NRG1, among others.
- These biomarkers should be determined by local laboratory, external vendor, or next generation sequencing platform
- Decision to consider clinical trial pre-screening enrollment (CTE) by primary provider and/or patient
Key exclusion criteria (3 listed)
- ECOG PS > 2;
- Abnormal organ function;
- Hospice enrollment
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Clinical Trial MatchingUsing a proprietary application programming interface (API) linked to existing electronic health records (EHR) platforms, individual clinical data is extracted, analyzed and matched to a parametric database of existing institutional and non-institutional CT. Machine learning algorithms allow for dynamic matching based on CT allocation and availability for optimized matching. | Other | Study Group |
Primary outcome
Proportion of patients Eligible for CTE versus Actual CTE
Time frame: Through study completion, an average of 1 year
CTE Accrual
6 secondary outcomes
Impact of CTE on Overall Survival (OS), estimated by Kaplan-Meier and Cox multivariable survival analysis
Time frame: 4 years
Impact of CTE on Progression-Free Survival (PFS), estimated by Kaplan-Meier and Cox multivariable survival analysis
Time frame: 4 years
Identification of Barriers to CTE
Time frame: Through study completion, an average of 1 year
Real World Data Analytics
Time frame: Through study completion, an average of 1 year
Virtual Tumor Board Utilization
Time frame: Through study completion, an average of 1 year
Time from Intervention to Actual CTE (months)
Time frame: Through study completion, an average of 1 year
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2025.
- Individual participant dataSharing planned: No
Related trials for Cancer, Metastatic
Active, not recruitingPhase 2
Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer
Recurrent Breast Carcinoma, Stage III Breast Cancer AJCC v7
Active, not recruitingPhase 3
A Study to Compare the Efficacy, Safety, Pharmacokinetics, and Immunogenicity Between SB27 and Keytruda in Subjects With Metastatic Non-squamous Non-small Cell Lung Cancer
Non-small Cell Lung Cancer Stage IV
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
Non-small Cell Lung Cancer
RecruitingPhase 2
A Phase II Trial of Tebentafusp in HLA-A*02:01 Positive Patients With Advanced Clear Cell Sarcoma
HLA-A*0201 Positive Cells Present, Clear Cell Sarcoma (CCS)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Selin Kurnaz, PhD principal investigator
Massive Bio, Inc.
68 sites in 2 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Cancer, Metastatic and Cancer, run by Massive Bio, Inc. at 68 sites in 2 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 28 Oct 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 68 sites in United States, Puerto Rico. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Fiona Evans, MS (+1 (844) 627-7246, fevans@massivebio.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Proportion of patients Eligible for CTE versus Actual CTE (time frame: Through study completion, an average of 1 year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2025; AzTrials last refreshed its copy on 26 Oct 2026.